ABT

MKT CAP:$159B

Abbott Laboratories

Market Cap

$159B

Healthcare·Medical - Devices·🇺🇸 United States·NYSE

Healthcare·Medical - Devices·🇺🇸·NYSE

Stock Price

$91.65-$32.54 (-26.20%)

Apr 24, 2026

Company Details

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, ...

CEO

Robert Ford

IPO Date

Mar 17, 1980

Website

www.abbott.com

Key Metrics TTM

Revenue

$45.1B

+6.6% YoY

Net Income

$6.3B

EPS (Diluted)

$3.59

Free Cash Flow

$7.4B

Revenue / Share

$25.84

Gross Margin

56.4%

Operating Margin

18.2%

Net Margin

13.9%

FCF Margin

16.4%

P/S

3.5x

P/E

25.4x

Earnings Reports

Q1 2026

Mar 30, 2026

$11.2B+7.8%EPS $0.62

FY 2025

Feb 20, 2026

$44.3B+5.7%EPS $3.72

Q4 2025

Feb 20, 2026

$11.5B+4.4%EPS $1.02

Q3 2025

Oct 29, 2025

$11.4B+6.9%EPS $0.94

Q2 2025

Jul 30, 2025

$11.1B+7.4%EPS $1.01

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 22	$11.3B	$5.8B	$2.3B
Q3 22	$10.4B	$5.2B	$1.7B
Q4 22	$10.1B	$5.0B	$1.4B
Q1 23	$9.7B	$4.8B	$1.4B
Q2 23	$10.0B	$4.9B	$1.5B
Q3 23	$10.1B	$5.0B	$1.7B
Q4 23	$10.2B	$5.3B	$1.9B
Q1 24	$10.0B	$5.0B	$1.4B
Q2 24	$10.4B	$5.3B	$1.7B
Q3 24	$10.6B	$5.4B	$1.8B
Q4 24	$11.0B	$5.6B	$2.0B
Q1 25	$10.4B	$5.4B	$1.7B
Q2 25	$11.1B	$6.3B	$2.1B
Q3 25	$11.4B	$6.3B	$2.1B
Q4 25	$11.5B	$6.5B	$2.3B
Q1 26	$11.2B	$6.3B	$1.8B

Valuation

Quarter	P/S	P/E
Q2 22	4.2x	22.3x
Q3 22	3.8x	21.9x
Q4 22	4.5x	28.2x
Q1 23	4.3x	30.5x
Q2 23	4.6x	36.1x
Q3 23	4.2x	32.2x
Q4 23	4.9x	34.1x
Q1 24	4.8x	34.5x
Q2 24	4.4x	32.2x
Q3 24	4.8x	34.2x
Q4 24	4.7x	14.6x
Q1 25	5.5x	17.2x
Q2 25	5.5x	17.0x
Q3 25	5.3x	16.6x
Q4 25	4.9x	33.4x
Q1 26	3.9x	28.4x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	$2.1B	$1.7B
Q2 22	$2.4B	$2.0B
Q3 22	$2.8B	$2.3B
Q4 22	$2.3B	$1.7B
Q1 23	$1.1B	$763M
Q2 23	$1.2B	$696M
Q3 23	$1.9B	$1.3B
Q4 23	$3.0B	$2.3B
Q1 24	$1.0B	$627M
Q2 24	$2.0B	$1.4B
Q3 24	$2.7B	$2.1B
Q4 24	$2.9B	$2.1B
Q1 25	$1.4B	$933M
Q2 25	$2.0B	$1.5B
Q3 25	$2.8B	$2.3B
Q4 25	$3.3B	$2.6B

Capital Expenditures

Quarter	CapEx
Q1 22	$321M
Q2 22	$379M
Q3 22	$467M
Q4 22	$610M
Q1 23	$380M
Q2 23	$507M
Q3 23	$560M
Q4 23	$755M
Q1 24	$398M
Q2 24	$533M
Q3 24	$556M
Q4 24	$720M
Q1 25	$484M
Q2 25	$502M
Q3 25	$496M
Q4 25	$689M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 22	+10.1%	+8.5%
Q3 22	-4.7%	+4.8%
Q4 22	-12.0%	-4.1%
Q1 23	-18.1%	-7.4%
Q2 23	-11.4%	-5.1%
Q3 23	-2.6%	-2.8%
Q4 23	+1.5%	-3.2%
Q1 24	+2.2%	+2.8%
Q2 24	+4.0%	+2.6%
Q3 24	+4.9%	+4.2%
Q4 24	+7.2%	+7.2%
Q1 25	+4.0%	+1.1%
Q2 25	+7.4%	+4.6%
Q3 25	+6.9%	+5.6%
Q4 25	+4.4%	+2.5%
Q1 26	+7.8%	+7.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$305M	2.6%
Q2 22	$142M	1.3%
Q3 22	$123M	1.2%
Q4 22	$115M	1.1%
Q1 23	$281M	2.9%
Q2 23	$132M	1.3%
Q3 23	$117M	1.2%
Q4 23	$114M	1.1%
Q1 24	$304M	3.1%
Q2 24	$141M	1.4%
Q3 24	$117M	1.1%
Q4 24	$111M	1.0%
Q1 25	$289M	2.8%
Q2 25	$142M	1.3%
Q3 25	$120M	1.1%
Q4 25	$113M	1.0%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q2 22	$684M	—	$2.8B
Q3 22	$780M	—	$2.7B
Q4 22	$691M	—	$2.8B
Q1 23	$654M	—	$2.8B
Q2 23	$710M	—	$2.7B
Q3 23	$661M	—	$2.7B
Q4 23	$690M	—	$2.7B
Q1 24	$683M	—	$3.0B
Q2 24	$697M	—	$2.9B
Q3 24	$713M	—	$2.9B
Q4 24	$728M	—	$2.9B
Q1 25	$703M	—	$3.1B
Q2 25	$732M	—	$3.1B
Q3 25	$785M	—	$3.1B
Q4 25	$735M	$3.1B	—
Q1 26	$756M	—	$3.3B

Revenue Segments

Quarter	Diagnostic Products	Established Pharmaceutical Products	Medical Devices	Nutritional Products	Unallocated Amount to Segment
Q2 22	$4.3B	$1.2B	$3.8B	$2.0B	$2M
Q3 22	$3.9B	$1.3B	$3.6B	$1.8B	—
Q4 22	$3.1B	$1.2B	$3.8B	$1.8B	—
Q1 23	$2.7B	$1.2B	$3.9B	$2.0B	—
Q2 23	$2.1B	$1.3B	$4.3B	$2.1B	—
Q3 23	$2.4B	$1.4B	$4.2B	$2.1B	—
Q4 23	$2.8B	$1.2B	$4.4B	$2.0B	—
Q1 24	$2.2B	$1.2B	$4.5B	$2.1B	—
Q2 24	$2.2B	$1.3B	$4.7B	$2.1B	—
Q3 24	$2.4B	$1.4B	$4.7B	$2.1B	—
Q4 24	$2.5B	$1.3B	$5.1B	$2.1B	—
Q1 25	$2.1B	$1.3B	$4.9B	$2.1B	—

Revenue by Geography

Quarter	Non-US	United States
Q2 22	$6.4B	$4.9B
Q3 22	$6.3B	$4.1B
Q4 22	$5.9B	$4.2B
Q1 23	$5.8B	$3.9B
Q2 23	$6.2B	$3.8B
Q3 23	$6.3B	$3.8B
Q4 23	$6.3B	$3.9B
Q1 24	$6.1B	$3.8B
Q2 24	$6.4B	$3.9B
Q3 24	$6.4B	$4.2B
Q4 24	$6.6B	$4.3B
Q1 25	$6.2B	$4.2B
Q2 25	$6.9B	$4.3B
Q3 25	$7.1B	$4.3B

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$7.7B	$483M	$8.2B
Q2 22	$8.9B	$353M	$9.3B
Q3 22	$9.6B	$313M	$9.9B
Q4 22	$9.9B	$288M	$10.2B
Q1 23	$9.2B	$371M	$9.5B
Q2 23	$7.8B	$320M	$8.2B
Q3 23	$6.7B	$338M	$7.0B
Q4 23	$6.9B	$383M	$7.3B
Q1 24	$6.3B	$367M	$6.7B
Q2 24	$7.0B	$232M	$7.2B
Q3 24	$7.6B	$230M	$7.8B
Q4 24	$7.6B	$351M	$8.0B
Q1 25	$6.5B	$312M	$6.8B
Q2 25	$7.0B	$331M	$7.3B
Q3 25	$7.5B	$222M	$7.7B
Q4 25	$8.5B	$417M	$8.9B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 22	1.76B	-0.6%	-1.6%
Q3 22	1.76B	-0.1%	-1.4%
Q4 22	1.75B	-0.6%	-1.6%
Q1 23	1.75B	-0.1%	-1.3%
Q2 23	1.75B	-0.1%	-0.8%
Q3 23	1.75B	-0.1%	-0.9%
Q4 23	1.75B	-0.0%	-0.3%
Q1 24	1.75B	+0.1%	-0.1%
Q2 24	1.75B	+0.1%	+0.0%
Q3 24	1.75B	-0.2%	-0.0%
Q4 24	1.75B	-0.1%	-0.1%
Q1 25	1.75B	+0.1%	-0.2%
Q2 25	1.75B	+0.2%	0.0%
Q3 25	1.75B	-0.1%	+0.1%
Q4 25	1.75B	-0.1%	+0.1%
Q1 26	1.75B	0.0%	-0.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 22	$99.6K	113K
Q3 22	$92.1K	113K
Q4 22	$87.7K	115K
Q1 23	$84.8K	115K
Q2 23	$86.8K	115K
Q3 23	$88.2K	115K
Q4 23	$89.8K	114K
Q1 24	$87.4K	114K
Q2 24	$91.0K	114K
Q3 24	$93.3K	114K
Q4 24	$96.3K	114K
Q1 25	$90.9K	114K
Q2 25	$97.7K	114K
Q3 25	$99.7K	114K
Q4 25	$99.6K	115K
Q1 26	$97.1K	115K

Revenue / Employee